• Bestatin (Ubenimex): Precision Aminopeptidase Inhibition in

  2026-05-26

  Bestatin (Ubenimex) is a gold-standard aminopeptidase inhibitor, transforming multidrug resistance (MDR) research and apoptosis assay workflows with unmatched selectivity and nanomolar potency. Discover protocol-driven troubleshooting strategies and innovative applications that put APExBIO’s Bestatin at the core of next-generation cancer and antimalarial studies.

• Atorvastatin: HMG-CoA Reductase Inhibitor in Research Contex

  2026-05-26

  Atorvastatin is a widely used HMG-CoA reductase inhibitor with proven efficacy in cholesterol metabolism research and cardiovascular disease models. Recent studies demonstrate its additional utility in inducing ferroptosis in hepatocellular carcinoma cells. This dossier provides a fact-based overview, supported by peer-reviewed evidence and product documentation.

• BMAL1 Phase Separation Controls Circadian Transcriptional Hu

  2026-05-25

  This study uncovers that BMAL1, a core circadian regulator, forms dynamic phase-separated nuclear condensates whose assembly and function are modulated by its N-terminal intrinsically disordered region and phosphorylation state. These biomolecular condensates serve as transcriptional hubs, providing a mechanistic basis for delayed gene activation and the robustness of circadian rhythms in mammals.

• PEDV Exploits IMPDH-Dependent Nucleotide Metabolism for Repl

  2026-05-25

  This study reveals that porcine epidemic diarrhea virus (PEDV) manipulates host IMPDH-dependent guanine nucleotide biosynthesis to enhance its replication. Both genetic and pharmacological inhibition of IMPDH, including with Merimepodib (VX-497), significantly suppress PEDV propagation, positioning IMPDH as a promising host-targeted antiviral strategy.

• Talin1–Piezo1–YAP Axis in Endothelial Inflammation and Ather

  2026-05-24

  This study elucidates how Talin1 modulates the Piezo1–YAP signaling axis to drive endothelial inflammation in atherosclerosis models. By defining the role of calcium influx in this pathway, the research highlights new opportunities for targeted anti-inflammatory intervention in vascular disease.

• Ibotenic Acid: Circuit Dissection and Precision in Pain Mode

  2026-05-23

  Explore how Ibotenic acid empowers neuroscience research as an NMDA receptor agonist, uniquely enabling precise manipulation of neural circuits for pain and neurodegeneration modeling. This article reveals advanced applications, referencing new insights into brain-to-spinal circuit control.

• Dihydroartemisinin: Advanced Protocols for Malaria & mTOR Re

  2026-05-22

  Dihydroartemisinin, a potent Artemisia plant extract, empowers researchers with precise inhibition of the mTOR signaling pathway and robust antimalarial activity. This guide details applied workflows, troubleshooting strategies, and practical insights that set APExBIO’s high-purity dihydroartemisinin apart for translational and bench research.

• Aminopeptidase Inhibitors in Next-Gen Cancer Therapy: Findin

  2026-05-22

  This review positions aminopeptidase inhibitors, especially Bestatin (Ubenimex), as key agents in next-generation cancer therapy through their mechanistic role downstream of the ubiquitin-proteasome pathway. The study synthesizes evidence on the physiological and therapeutic relevance of aminopeptidases, highlighting how selective inhibition can inform combination chemotherapy strategies.

• Enhancing Early Diabetic Nephropathy Biomarker Discovery wit

  2026-05-21

  This thought-leadership article explores how Cy3 Goat Anti-Rabbit IgG (H+L) Antibody empowers translational researchers to surmount immunofluorescence challenges in biomarker discovery for early diabetic nephropathy. It integrates mechanistic insights from recent quantitative proteomics findings, critically examines the evolving antibody landscape, and offers protocol guidance for robust, reproducible signal amplification in advanced immunoassays.

• Deferasirox Fe3+ Chelate: Mechanism and Benchmarks in Iron O

  2026-05-21

  Deferasirox Fe3+ chelate is a high-purity, DMSO-soluble oral iron chelator used in iron overload treatment research. Its defined Fe3+ binding mechanism and impact on myeloid differentiation make it a benchmark compound for beta-thalassemia and chronic anemia studies. APExBIO supplies the compound for rigorously controlled scientific research applications.

• Tofacitinib (CP-690550): Optimizing Immune Modulation Workfl

  2026-05-20

  Tofacitinib (CP-690550) stands out as a selective JAK1/JAK3 inhibitor, enabling precise inhibition of interleukin signaling and functional immune modulation in advanced cell models. This article delivers practical guidance for experimental workflows, protocol fine-tuning, and troubleshooting strategies—empowering researchers to translate mechanistic insights into reproducible, high-impact immune cell assays.

• Cell Cycle Assay Kit (K2263): Unraveling Cell Fate in Cancer

  2026-05-20

  Explore how the Cell Cycle Assay Kit enables high-resolution analysis of cell cycle phases G0/G1, S, and G2/M, and advances apoptosis detection. This article offers a deeper, mechanism-driven perspective for oncology and translational research.

• Targeting SPP1 in Tumor-Associated Macrophages Reduces Tumor

  2026-05-19

  This study identifies small molecule inhibitors that selectively downregulate SPP1 in tumor-associated macrophages (TAM), providing a new strategy to curb tumor progression. By employing a phenotypic screen and a TAM-targeted nanoformulation, the research demonstrates significant tumor reduction in murine models, highlighting the therapeutic promise of SPP1 modulation.

• Metabolic Intervention Boosts Ferroptosis and Cuproptosis in

  2026-05-19

  The referenced study introduces a nanosystem-based metabolic intervention that synchronously enhances both ferroptosis and cuproptosis in tumor cells by targeting glycolysis and NAD+ metabolism. This dual activation strategy not only amplifies regulated cell death but also remodels the tumor immune microenvironment, offering a promising direction for advanced cancer therapies.

• Ferrocenyl Novobiocin Derivatives: Enhanced Activity Against

  2026-05-18

  This study by Mbaba et al. introduces ferrocenyl and organic novobiocin derivatives, evaluating their biological activity against Plasmodium falciparum and breast cancer cells. The work demonstrates that incorporating a ferrocene moiety into the novobiocin scaffold can improve antiparasitic and anticancer efficacy, offering new directions for aminocoumarin antibiotic optimization.

11807 records 2/788 page Previous Next 12345 下5页 Last page